A double blind, phase I/II, randomized, single and repeat dose, dose escalation study of the antibody BI-201 directed against Tat, given IV, versus Placebo in asymptomatic HIV-1 patients.
- Registry ID
- EUCTR2005-001019-23
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- BioInvent International AB
- Start date
- 2005-05-11
- Completion date
- 2006-02-07
- Last update
- 2026-08-16
Conditions
- HIV-1 (asymptomatic patients)
Summary
To monitor tolerability after single IV doses and after a short repeat dose regimen with initial loading doses (to achieve a rapid steady state serum level).
Locations
View on source registry